Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What MEDANTA guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 10 Nov 2026 | Global Health Limited (Medanta) filed the transcript of its Q2 FY27 and H1 FY27 earnings conference call held on November 4, 2026. Management reported Q2 FY27 consolidated revenue from operations of INR 14,690 million (up 34% YoY), operating EBITDA of INR 3,701 million (up 60% YoY, margin 25.2% vs 21%), and profit... NSE copy | No results filed since | ||
| 05 Aug 2026 | Global Health Limited (Medanta) filed the transcript of its Q1 FY27 earnings conference call held on July 31, 2026, for the quarter ended June 30, 2026. Management reported consolidated income of INR13,262 million (up 26% year-on-year) and reported EBITDA including Noida of INR3,153 million (up 23%, margin 23.8%);... NSE copy | +38.3 % | +33.6 % | +5.7 % |
| 20 May 2026 | Global Health Ltd (Medanta) filed the transcript of its Q4 and FY26 earnings conference call held on May 15, 2026. Management said FY26 total income rose 20% year-on-year to INR 45,089 million and consolidated profit after tax rose 15.1% to INR 5,541 million; Q4 FY26 total income was INR 11,958 million, up 25%,... NSE copy | -0.2 % | +26.5 % | -0.8 % |
| 09 Feb 2026 | Global Health Limited (Medanta) filed the transcript of its Q3 FY26 earnings conference call held on February 5, 2026, covering the quarter and nine months ended December 31, 2025. Management reported Q3 FY26 total income of Rs.11,428 million, up 19% year-on-year, and consolidated profit after tax of Rs.950... NSE copy | +42.0 % | +24.5 % | +2.5 % |
| 13 Nov 2025 | Global Health Limited (Medanta) filed the transcript of its Q2 FY26 earnings conference call held on November 10, 2025, for the quarter ended September 30, 2025. Consolidated total income was INR 11,189 million, up 15% from INR 9,748 million a year earlier; PAT was INR 1,584 million, up 21%, with PAT margin of... NSE copy | -33.5 % | +18.8 % | -1.3 % |
| 21 May 2025 | Medanta (Global Health Ltd) filed the transcript of its Q4 and FY25 earnings conference call held on May 16, 2025. FY25 total consolidated income was INR 37,714 million (up 13% YoY); EBITDA INR 9,562 million (up 9%, margin 25.4%); reported PAT INR 4,813 million after one-time exceptional expenses of INR 499 million... NSE copy | +49.6 % | +19.7 % | +7.2 % |
| 16 May 2025 | Global Health Limited (Medanta) filed a revised investor presentation for Q4 and FY2025 results, dated 15 May 2025, under Regulation 30 of SEBI LODR, with the filing dated 16 May 2025. The company revised slides 13, 19, 22 and 26 and restated Matured and Developing hospital numbers due to the merger of MHPL... NSE copy | +49.6 % | +19.7 % | +7.2 % |
| 12 Feb 2025 | Global Health Ltd (Medanta) filed the transcript of its Q3 and 9M FY25 earnings conference call held on February 5, 2025. Management reported Q3 FY25 total income of Rs. 9,595 million (up 12% from Rs. 8,545 million), EBITDA of Rs. 2,538 million (up 8%, margin 27.5%) and profit after tax of Rs. 1,429 million (up... NSE copy | -20.4 % | +15.2 % | -3.4 % |
| 21 Nov 2024 | Global Health Ltd (Medanta) filed the transcript of its Q2 and H1 FY25 earnings conference call held on November 14, 2024, under Regulation 30 of SEBI LODR. Group CEO Pankaj Sahni said Q2 FY25 consolidated total income was INR 9,748 million (up 12.7% year on year), EBITDA INR 2,465 million (margin 25.3%) and PAT... NSE copy | +15.6 % | +13.3 % | +10.7 % |
Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 03 Nov 2026 | Legal or regulatory | Global Health Limited (Medanta) filed its investor presentation for Q2 and H1 FY2027 results (quarter ended September 30, 2026) on November 3, 2026. Q2 FY27 revenue from operations was INR 14,690 million, up 33.6% y-o-y; operating EBITDA was INR 3,701 million (margin 25.2%) versus 21.0% in Q2 FY26. Profit after tax... NSE copy |
| 30 Jul 2026 | Management change | Global Health Limited (Medanta) board meeting held July 30, 2026 approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from Walker Chandiok & Co LLP enclosed. The board fixed Friday, August 14, 2026 as record date for final dividend of Rs.... NSE copy |
| 30 Jul 2026 | Management change | Global Health Limited (Medanta) board meeting outcome dated July 30, 2026: approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from Walker Chandiok & Co LLP enclosed. Board fixed August 14, 2026 as record date for final dividend of Rs.... NSE copy |
| 14 May 2026 | Management change | Global Health Limited (Medanta) board outcome dated May 14, 2026: approved audited standalone and consolidated results for Q4 and FY ended March 31, 2026, with unmodified auditor report from Walker Chandiok & Co LLP. Board recommended final dividend of Rs. 0.50 per equity share (25% on face value of Rs. 2), subject... NSE copy |
| 14 May 2026 | Management change | Global Health Limited (Medanta) board meeting outcome dated May 14, 2026: approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with unmodified auditor report from Walker Chandiok & Co LLP. Board recommended a final dividend of Rs. 0.50 per equity share (25%) on face... NSE copy |
| 04 Feb 2026 | Management change | Board of Global Health Limited (Medanta) approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with limited review reports from Walker Chandiok & Co LLP (Annexure A). Board approved appointment of Mr. Malik Mohd. Ashhab as Senior Management... NSE copy |
| 16 Dec 2025 | Credit rating | Global Health Limited (Medanta) filed an intimation under Regulation 30 of SEBI LODR regarding a revised credit rating letter from CRISIL Ratings dated December 16, 2025. Total bank loan facilities rated: Rs. 1,500 crore. Long-term rating upgraded to CRISIL AA/Stable from CRISIL AA-/Positive. Short-term rating... NSE copy |
| 13 Nov 2025 | Management change | Global Health Limited (Medanta) filed the transcript of its Q2 FY26 earnings conference call held on November 10, 2025, for the quarter ended September 30, 2025. Consolidated total income was INR 11,189 million, up 15% from INR 9,748 million a year earlier; PAT was INR 1,584 million, up 21%, with PAT margin of... NSE copy |
| 17 Oct 2025 | Credit rating | Global Health Limited (Medanta) filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit rating from CRISIL Ratings. CRISIL Ratings issued a revised credit rating letter dated October 16, 2025, adding bank names to the company's facilities. Total bank loan facilities rated: Rs. 1500 crore,... NSE copy |
| 15 Aug 2025 | Management change | Global Health Limited (Medanta) filed the transcript of its Q1 FY26 earnings conference call held on August 08, 2025. Management (Group CEO Pankaj Sahni) said Q1 FY26 total income was INR10,513 million, up 19% year-on-year, and EBITDA was INR2,553 million, up 23%, with a 24.3% margin. Profit after tax was INR1,590... NSE copy |
| 07 Aug 2025 | Management change | Global Health Limited (Medanta) board outcome dated August 7, 2025: approved unaudited standalone and consolidated results for the quarter ended June 30, 2025, with limited review reports from Walker Chandiok & Co LLP. Board fixed August 22, 2025 as record date for final dividend of Rs. 0.50 per equity share for FY... NSE copy |
| 15 May 2025 | Management change | Global Health Limited (Medanta) filed its investor presentation for the fourth quarter and financial year ended March 31, 2025. The presentation covers FY2025 year-at-a-glance, FY2025 and Q4 FY2025 performance updates, project updates and capex plan. Management reports 219 beds added during FY2025, a 7.8% bed... NSE copy |
| 15 May 2025 | Management change | Global Health Limited (Medanta) filed the outcome of its board meeting held May 15, 2025, approving audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2025. The board recommended a final dividend of Rs. 0.50 per equity share (25% on face value of Rs. 2), subject to... NSE copy |
| 15 May 2025 | Management change | Global Health Limited (Medanta) filed the outcome of its May 15, 2025 board meeting, which approved audited standalone and consolidated financial results for Q4 and the year ended March 31, 2025. The board recommended a final dividend of Rs. 0.50 per equity share (25% on face value of Rs. 2), subject to shareholder... NSE copy |
| 18 Mar 2025 | Credit rating | Intimation to BSE and NSE of a credit rating from CRISIL Ratings for Global Health Limited (Medanta), dated March 18, 2025. Total bank loan facilities rated enhanced to Rs 1,500 crore from Rs 950 crore, following the merger of wholly owned subsidiary Medanta Holdings Private Limited with the company. CRISIL... NSE copy |
| 01 Mar 2025 | Legal or regulatory | Intimation under Regulation 30 of SEBI LODR that the NCLT (New Delhi Bench-V) approved Scheme of Amalgamation between Medanta Holdings Private Limited (wholly-owned subsidiary) and Global Health Limited has been filed with the Registrar of Companies, NCT of Delhi & Haryana on March 01, 2025. Once formally noted by... NSE copy |
| 21 Feb 2025 | Legal or regulatory | Global Health Limited (Medanta) filed intimation under Regulation 30 of SEBI LODR regarding the final order of the NCLT New Delhi Bench (order dated 20.02.2025). The NCLT sanctioned the Scheme of Amalgamation between Medanta Holdings Private Limited (wholly-owned subsidiary, transferor) and Global Health Limited... NSE copy |
| 20 Feb 2025 | Legal or regulatory | The company filed an intimation under Regulation 30 of SEBI LODR regarding the final order of the Hon'ble National Company Law Tribunal, New Delhi Bench. The NCLT approved the Scheme of Amalgamation between Medanta Holdings Private Limited (a wholly-owned subsidiary) and Global Health Limited, under Sections 230 to... NSE copy |
| 12 Feb 2025 | Management change | Global Health Ltd (Medanta) filed the transcript of its Q3 and 9M FY25 earnings conference call held on February 5, 2025. Management reported Q3 FY25 total income of Rs. 9,595 million (up 12% from Rs. 8,545 million), EBITDA of Rs. 2,538 million (up 8%, margin 27.5%) and profit after tax of Rs. 1,429 million (up... NSE copy |
| 05 Feb 2025 | Credit rating | Medanta (Global Health Limited) filed an intimation under Regulation 30 on credit rating dated February 5, 2025. CRISIL Ratings reaffirmed long-term rating at CRISIL AA-/Positive and short-term rating at CRISIL A1+. Total rated bank loan facilities increased to Rs. 950 crore from Rs. 500 crore. The facilities... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (24 in all). A list of what was filed, not a judgement of the company.